Agenus inc. receives $10 million from urogen pharma for rights to zalifrelimab (ctla-4)

Agenus inc. announced that it received$10m upfront for a license agreement with urogen pharma ltd. under the agreement agenus is providing access to zalifrelimab (agen1884, anti-ctla-4 antibody) for use with urogen's sustained release technology for intravesical delivery in patients with urinary tract cancers.  it is conducting clinical trials for zalifrelimab in combination with agenus' anti-pd-1 antibody balstilimab (agen2034) for a planned bla filing in cervical cancer. in addition, zalifrelimab is being evaluated as a monotherapy in pd-1 refractory patients. under the terms of the agreement, in addition to the $10 million upfront payment, agenus is eligible to receive up to $200 million in potential development, regulatory and commercial milestones, as well as 14-20% royalties on net sales.
AGEN Ratings Summary
AGEN Quant Ranking